ValuEngine downgraded shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a hold rating in a research report released on Friday morning.

Several other research analysts also recently commented on the stock. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, October 9th. B. Riley upped their price target on shares of Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the stock a neutral rating in a report on Monday, September 17th. Citigroup assumed coverage on shares of Dicerna Pharmaceuticals in a report on Thursday, September 13th. They set a buy rating and a $27.00 price target for the company. SunTrust Banks upped their price target on shares of Dicerna Pharmaceuticals to $20.00 and gave the stock a buy rating in a report on Thursday, September 6th. Finally, Cowen reiterated a buy rating on shares of Dicerna Pharmaceuticals in a report on Wednesday, September 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Dicerna Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $17.41.

DRNA traded down $1.32 during trading on Friday, hitting $11.76. 866,698 shares of the stock traded hands, compared to its average volume of 586,323. Dicerna Pharmaceuticals has a twelve month low of $4.91 and a twelve month high of $17.98. The company has a market cap of $808.43 million, a P/E ratio of -3.21 and a beta of 2.43. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 5.40.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The firm had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.79 million. On average, analysts expect that Dicerna Pharmaceuticals will post -1.13 earnings per share for the current fiscal year.

In other news, insider James B. Weissman sold 2,301 shares of the company’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $17.50, for a total transaction of $40,267.50. Following the completion of the transaction, the insider now directly owns 26,781 shares in the company, valued at $468,667.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total transaction of $232,496.00. Following the transaction, the director now owns 29,064 shares of the company’s stock, valued at $465,024. The disclosure for this sale can be found here. 19.85% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Dicerna Pharmaceuticals in the first quarter worth $102,000. Jane Street Group LLC bought a new stake in shares of Dicerna Pharmaceuticals in the first quarter worth $136,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Dicerna Pharmaceuticals in the second quarter worth $178,000. Verition Fund Management LLC bought a new stake in shares of Dicerna Pharmaceuticals in the first quarter worth $141,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in shares of Dicerna Pharmaceuticals in the second quarter worth $188,000. 74.59% of the stock is currently owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Story: Terms to Better Understand Call Options

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.